EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT ‐1 Randomized Controlled Trial

Tomoaki Morioka, Daichi Miyaoka iD, Susumu Nakatani, Yoshinori Kakutani, Shoko Miyamoto, Yu Nagakura, Miho Uematsu, Takehiro Hirano, Hidekatsu Yae, Mako Yamamoto, Noriaki Sato, Kosuke Fujimoto und 3 weitere

Diabetes, Obesity and Metabolism · 08.11.2026

DOI: 10.1111/dom.71533 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.11.2026. Verfasst von Tomoaki Morioka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism, Endocrinology and Molecular Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Glucagon‐like peptide‐1‐based therapies improve metabolic outcomes, but longitudinal gut microbiome dynamics remain poorly characterized. We compared taxonomic and predicted functional microbiome responses to tirzepatide and semaglutide in Type 2 diabetes. Materials and Methods This exploratory secondary analysis included 36 participants from a randomized controlled trial comparing tirzepatide, semaglutide and conventional treatment. Faecal samples were collected at five time points over 16 weeks and analyzed by 16S rRNA gene sequencing. Genus‐level features were screened using MaAsLin2, and candidate genera were further evaluated using longitudinal mixed‐effects models. Predicted microbial functions were inferred using PICRUSt2 and analyzed using MaAsLin2. Primary analyses were adjusted for baseline body mass index, with exploratory sensitivity analyses additionally adjusted for changes in body weight and haemoglobin A1c.

Results

No significant between‐group differences in beta diversity were observed. Alpha diversity increased predominantly in the tirzepatide group, with a significant time‐by‐treatment interaction versus control. Longitudinal trajectories relative to the control group differed for several genera, including Romboutsia_B , Barnesiella and Ruminococcus_E with both treatments and Vescimonas with tirzepatide ( q < 0.05). Across 2106 predicted EC features, longitudinal effects were positively correlated between tirzepatide and semaglutide (67.1% concordant direction; Pearson r = 0.450, p < 0.001). Treatment‐versus‐control analyses identified predicted functional changes involving energy and carbohydrate metabolism.

Conclusions

Tirzepatide and semaglutide were associated with partially distinct taxonomic changes, accompanied by broadly similar predicted functional patterns. These longitudinal findings complement, while remaining distinct from, Week‐16 shotgun metagenomic endpoint analyses. Trial Registration Japan Registry of Clinical Trials (jRCT), jRCT1051240017

Schlagwörter

Stichwörter der Autor:innen

16S rRNA gene sequencingType 2 diabetesgut microbiomelongitudinal analysissemaglutidetirzepatide

Autor:innen und Institutionen

  • Department of Metabolism, Endocrinology and Molecular Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Department of Immunology and Genomics, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Division of Metagenome Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Department of Microbial Regulation, Research Institute for Microbial Diseases, The University of Osaka, Osaka, Japan.

ORCID-Profile: Daichi Miyaoka

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Morioka, T., Miyaoka, D., Nakatani, S., Kakutani, Y., Miyamoto, S., Nagakura, Y., Uematsu, M., Hirano, T., Yae, H., Yamamoto, M., Sato, N., Fujimoto, K., Emoto, M., Imoto, S., & Uematsu, S. (2026). Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT ‐1 Randomized Controlled Trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71533

Vancouver

Morioka T, Miyaoka D, Nakatani S, Kakutani Y, Miyamoto S, Nagakura Y, et al. Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT ‐1 Randomized Controlled Trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71533

BibTeX
@article{Morioka2026,
  author = {Morioka, Tomoaki and Miyaoka, Daichi and Nakatani, Susumu and Kakutani, Yoshinori and Miyamoto, Shoko and Nagakura, Yu and Uematsu, Miho and Hirano, Takehiro and Yae, Hidekatsu and Yamamoto, Mako and Sato, Noriaki and Fujimoto, Kosuke and Emoto, Masanori and Imoto, Seiya and Uematsu, Satoshi},
  title = {Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT ‐1 Randomized Controlled Trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71533}
}
Kostenlos starten →